Adipocytes as an Important Source of Serum S100B and Possible Roles of  This Protein in Adipose Tissue by Gonçalves, Carlos Alberto et al.
Hindawi Publishing Corporation
Cardiovascular Psychiatry and Neurology
Volume 2010, Article ID 790431, 7 pages
doi:10.1155/2010/790431
Review Article
Adipocytesas an Important Source of Serum S100B and
Possible Roles of This Protein in Adipose Tissue
CarlosAlberto Gonc ¸alves, MarinaConcli Leite, and Maria CristinaGuerra
Departamento de Bioqu´ ımica, Instituto de Ciˆ encias B´ asicas da Sa´ ude, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos,
2600-Anexo, 90035-003 Porto Alegre, RS, Brazil
Correspondence should be addressed to Carlos Alberto Gonc ¸alves,casg@ufrgs.br
Received 1 April 2010; Accepted 17 May 2010
Academic Editor: Claus W. Heizmann
Copyright © 2010 Carlos Alberto Gonc ¸alves et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Adipocytes contain high levels of S100B and in vitro assays indicate a modulated secretion of this protein by hormones that
regulate lipolysis, such as glucagon, adrenaline, and insulin. A connection between lipolysis and S100B release has been proposed
but deﬁnitive evidence is lacking. Although the biological signiﬁcance of extracellular S100B from adipose tissue is still unclear,
it is likely that this tissue might be an important source of serum S100B in situations related, or not, to brain damage. Current
knowledge does not preclude the use of this protein in serum as a marker of brain injury or astroglial activation, but caution
is recommended when discussing the signiﬁcance of changes in serum levels where S100B may function as an adipokine, a
neurotrophic cytokine, or an alarmin.
1.Introduction
Searchingforperipheralmolecularmarkersforbraindamage
and/or dysfunction, S100B protein appears to be a promising
candidate [1–6]. In fact, studies in serum samples, after
acute brain injury, show that S100B levels change; however
the interpretation of results is complex, particularly because
extracerebral sources contribute to the serum S100B content.
Herein, we intend to discuss S100B from adipocytes as a
source for the serum content of this protein and to compare
the release of S100B from adipocytes with that of astrocytes,
the major S100B-containing compartment in the central
nervous system. We hope that this paper can contribute to
the search for the biological role(s) of this protein in adipose
tissue, as well as to help to understand how variations in the
serum content of S100B aﬀect physiological and pathological
conditions.
2.Adipocytes
It is important to take into consideration some points
about adipocytes, which are the target cells of this paper.
Adipocytes are the main cell type in adipose tissue, which
is distributed in three major anatomical areas: subcutaneous,
dermalandintraperitoneal[7].Thepopulationofadipocytes
is heterogeneous in each area and subarea, based on their
size and proliferative capacity, and also may be variable,
depending on the region’s blood ﬂow and innervation
density. In addition to adipocytes, adipose tissue contains
stromal-vascular cells and immune cells and the traditional
concept that tissue is a simple lipid store is no longer
valid [8]. In fact, some adipocyte-derived proteins are
messengers, acting on speciﬁc receptors found in endothelial
cells,musclecells,cardiomyocytesandneuronsanddisorders
of communication between these cells are associated, for
example, with diabetes and cardiovascular disorders [8, 9].
3.S100B inAdipocytes
S100B was initially described as a neuron-speciﬁc protein
[10], but subsequent characterization revealed that this pro-
tein, in the central nervous system (CNS), is mainly localized
in GFAP positive glial cells [11]. However, in the CNS, this
protein was also abundantly detected in oligodendrocytes
[12],inmicroglia[13]andevenincholinergicneuronsofthe2 Cardiovascular Psychiatry and Neurology
hindbrain [14]. Moreover, it was also found among various
cells of non-neural tissues [15, 16], such as adipocytes [17],
chondrocytes [18] and melanoma cells [19].
The ﬁrst evidence of S100B in adipose tissue was
independently obtained by Hidaka and coworkers, in Japan
[20]a n db yM i c h e t t ia n dc o w o r k e r s ,i nI t a l y[ 17]. Hidaka
et al. found elevated levels of S100B in brain tissue, using a
polyclonal anti-S100B and Michetti et al. found that S-100
protein in adipose tissue was comparable to that measured in
the brain tissue, but that possibly S100A1 was also present in
the preparation. Regardless of this, these studies contribute
to consolidate the view that S100B exists in non-nervous
tissues [18, 19].
The mRNA expression of S100B was demonstrated later
inadiposetissue[21].Itisimportanttomentionthatadirect
correlation between the mRNA and protein levels was not
observed. This absence of correlation also was observed in
brain and adipose tissue in rats exposed to streptozotocin, a
drug used to induce type 1 diabetes [22]. These data suggest
a complex and cell-speciﬁc mechanism of S100B expression
[23].
Preliminary results from Guaragna in our laboratory
indicate that human adipose tissue also expresses high levels
of S100B and that this amount varies depending on the
anatomical area of adipose tissue. In rats, we found an
elevated content of S100B in rat white adipose epididymal
tissue (about 1.5ng/μg of protein), comparable to that of
the hippocampal tissue [24], but sample delipidation is a
necessary experimental procedure to avoid an underestima-
tion of S100B content in adipose tissue [25]. Moreover, both
adipose and brain tissues increase S100B protein content
when exposed to streptozotocin in diabetes or dementia
models [22, 26].
4.IsS100B Releasedby Adipocytes?
There is clear evidence that adipocytes release S100B in
diﬀerent cell preparations, including epidydimal fat pad and
freshly-isolated adipocytes (Table 1). Based on cell integrity
assay (lactate dehydrogenase release), the mechanism of
S100B release from adipocytes should be appropriately
referred to as S100B secretion, as occurs in astrocytes and
diﬀers,forexample,fromS100Breleasefrommelanomacells
[34]. A positive regulation of S100B secretion in adipocytes
was observed in response to glucagon and catecholamines,
likely triggered by a cAMP-mediated pathway, as occurs in
astrocytes [35]. Insulin, which attenuates the cAMP pathway
in adipocytes, caused a decrease in S100B release [31].
Nevertheless, it is important to evaluate whether this
secretion could aﬀect serum S100B levels. In other words,
should variations in amount and activity of adipose tissue
be considered in the interpretation of serum S100B levels?
HumanBraintissuecorrespondsto2%ofweightbody,while
adipose tissue corresponds, in normal individuals, to 9–18%
in men and 14–28% in women [7]. Thus, considering the
amount and the in vitro secretion rate of S100B from the
adipose tissue, it is reasonable to assume that this tissue
is an important source of serum S100B that is even more
important than brain tissue.
Some evidence to support this hypothesis arose during
physical exercise conditioning studies, where serum S100B
elevations, putatively, were not associated with brain dam-
age; such exercise included swimming racing [36], marathon
running [37] and playing basketball [38]. The suspicion that
body weight could aﬀect serum S100B levels was examined
in a study in bipolar patients [39]. Two independent
studies in anorexic patients indicate a relationship between
serum S100B and body weight [40, 41]. However, an
appropriate study about this issue was performed only more
recently [42]. Steiner’s group correlated mass body index
(BMI), serum levels of S100B and two well-characterized
adipose-derived proteins: leptin and adipocyte-type fatty
acid-binding protein (A-FABP) in individuals without a
prior history of neurological or psychiatric disorders. They
observed that S100B levels were closely correlated with the
b o d ym a s si n d e x ,a sw e l la sl e v e l so fl e p t i na n dA - F A B P .
In support of these ﬁndings, we investigated the levels
of serum and CSF S100B in 48-h-fasting Wistar rats [33].
A signiﬁcant (more than two-fold) increase in serum S100B
levels was observed in these rats, without changes in
cerebrospinal ﬂuid S100B. These data are in agreement with
in vitro hormonal changes induced in the adipose tissue,
under stressing conditions, and suggest that S100B release
from adipocytes might be linked to lipolysis, but deﬁnitive
evidence is lacking.
5. Is There a Role for S100B in the Energy
Metabolismof Adipocytes?
Adipocytes, like other cells, have an intense glycolytic
metabolism (Figure 1). In the fed state, glucose intake goes
to fatty acids and then to triacylglycerol (lipogenesis). It is
important to mention that, in humans, fatty acid synthesis
occurs mainly in hepatocytes. Then fatty acids, converted
to triacylglycerols, are transferred and stored in adipose
tissue.Ontheotherhand,triacylglycerolstoresaremobilized
and brokendown to fatty acids and glycerol (lipolysis). In
fact, a permanent cycle of lipogenesis and lipolysis occurs
in adipose tissue, where about 70% of fatty acids released
during lipolysis arereesteriﬁed. However,becauseadipocytes
lack glycerol kinase, the glycolytic pathway provides glycerol-
phosphate to lipogenesis; in addition and importantly,
precursors of glucose, for example lactate (via pyruvate),
are used as a source of glycerol-phosphate in a pathway
denominated glyceroneogenesis (see [43]f o rar e v i e w ) .
Based on protein-binding assays, at least three putative
targets of S100B have been implicated in energy metabolism:
phosphoglucomutase [44], fructose-1,6-bisphosphate aldo-
lase [45] and glyceraldeyde 3-phosphate dehydrogenase [23].
Apparently, S100B may inhibit phosphoglucomutase and
stimulate aldolase. Together, these eﬀects lead to an increase
in the glycolytic pathway in adipocytes, which is coupled
to lipogenesis and reesteriﬁcation. However, the in vitro
eﬀects on the activity of these enzymes were preliminary
characterized 20 years ago by Zimmer et al. and additional
information is missing. Thus, until now a direct role of
intracellular S100B on glucose metabolism in adipocytes
(and astrocytes) remains a speculation.Cardiovascular Psychiatry and Neurology 3
Table 1: Evidence of modulated S100B release in adipocytes.
Modulatory Agent Eﬀect Preparation Reference
Catecholamines ↑ release epididymal fat pads [27]
Catecholamines ↓ intracellular content in vivo (adipose tissue) [28, 29]
Epinephrine, ACTH and cAMP ↑ release epididymal fat pads isolated adipocytes [30]
Insulin ↓ release epididymal fat pads [31]
Free fatty acids ↑ release epididymal fat pads [32]
Epinephrine
↑ release isolated adipocytes [33]
↑ basal release isolated adipocytes [25]
Glucose
Glycolysis
Glucose
? S100B
Lipogenesis
FFA FFA
? A-FABP
TAG
Lipolysis
cAMP
S100B
S100B
Figure 1: Schematic representation of the putative roles of S100B and
its secretion in adipocytes. cAMP (e.g., induced by catecholamines—
see Table 1) would trigger lipolysis and S100B secretion. The
connection between these events remains to be established, as well
as a role of S100B in the modulation of glycolysis (?) and in the
transport of free fatty acids (?). A-FABP, adipocyte type—fatty acid
binding protein; FFA, free fatty acids; TGA, triacylglycerol.
Moreover, the cAMP pathway, triggered by adrenaline
and glucagon (and attenuated by insulin), which results in
lipolysis(seeTable 1),could,inparallel,beinvolvedinS100B
release (Figure 1). In fact, cAMP modulates S100B secretion
in adipocytes [27, 31]a n da s t r o c y t e s[ 35, 46]. Twenty-ﬁve
years ago, Suzuki and Kato suggested that S100B could serve
as a carrier protein of fatty acids [31]. However, it is not
clear whether S100B release is connected to the mechanism
of lipolysis induced by cAMP. It is important to mention
that some members of the S100 family, such as S100A7, A8
and A9, modulate fatty acid transport in keratinocytes and
neutrophils due to the interaction with fatty acid-binding
proteins(FABP)[47,48].Interestingly,Steineretal.observed
a strong correlation between serum circulating levels of
S100B and adipocyte-type FABP (A-FABP) [42]. So far,
however, no study has investigated a biochemical interaction
between S100B and A-FABP.
6. What Is the Role of
S100B Release byAdipocytes?
Regardless of whether S100B is released, or not, from
adipocytes during lipolysis, it is also important to evaluate
the extracellular role of this protein, that is, could have
this protein an autocrine, a paracrine or an endocrine
role? As yet, RAGE—the Receptor for Advanced Glycation
End products (AGE)—is the only characterized receptor for
S100B [49, 50] and, thus, we should discuss the possible
extracellular eﬀects of adipocyte-derived S100B based on
RAGE activation. However, eﬀects of S100B, independent of
RAGE, cannot be rule out (e.g., [13]). Moreover, the eﬀect
of RAGE activation depends upon ligand, that is, RAGE
activation by BSA-AGE or S100B does not necessarily induce
the same response [51, 52]. The diversity of eﬀects induced
by RAGE activation are not only due to cell-speciﬁcity, but
also depend on the oligomeric organization of the ligand (in
the case of S100 proteins), as well as RAGE oligomerization
[53, 54].
RAGE activation by AGE in cultures of adipocytes
inhibited glucose uptake through the overgeneration of
intracellular reactive oxygen species [55] and this could
contribute to insulin resistance. Notice that in vitro S100B
release by adipocytes is even higher than that of astrocytes
[25]. Thus, beneﬁcial or detrimental autocrine eﬀects could
be conceived. However, the direct eﬀect of S100B on
adipocytes has not been investigated until now.
Locally concentrated extracellular S100B in adipose
tissue could exert an eﬀect on neighbor cells. The innate
immune response could be induced by S100B, recruiting
monocytes [56] and activating macrophages [57], both
in a manner that depends on RAGE. Moreover, also via
RAGE, S100B is potentially able to increase endothelial
adherence to leucocytes [58], to reduce vasodilatation
induced by acetylcholine [59] and to increase neovascu-
lar proliferation [60]. Taken together, these eﬀects could
indicate a proinﬂammatory eﬀect of RAGE activation by
S100B, as has been proposed [61]. This is in agreement
with the idea that adipocyte-derived proteins contribute to
systemic inﬂammatory responses (e.g., [62]). However, a
speciﬁc contribution of S100B to paracrine communication
in adipose tissue demands further investigation, possibly
providing a target for therapeutic intervention in obesity,
diabetes and cardiovascular diseases.4 Cardiovascular Psychiatry and Neurology
With regard to any endocrine activity of the S100B
released from adipocytes, two tissue targets could be pro-
posed: the brain and heart, but weak biochemical bases of
these connections can be established. S100B is not normally
expressed in the myocardium, but it is induced in the peri-
infarct region and potentially modulates myocyte apoptosis
(see [63] for a review). Exogenous addition of S100B to
cardiacmyocyteculturesisabletocauseapoptosisviaRAGE,
at a concentration of higher than 50nM, a level that may
be achieved in the peri-infarct local [64]. This concentration
is 10,000 × higher than serum S100B. Thus, based on
current evidence, it is quite diﬃcult to conceive an endocrine
eﬀectofS100B,releasedfromadipocytes,oncardiomyocytes.
Furthermore, it is diﬃcult to hypothesize an eﬀect of S100B
from adipocytes on neurons of the CNS, as the basal levels
of extracellular S100B (from astrocytes and possibly from
other neural cells) surpass serum levels. Therefore, the eﬀect
of S100B in the heart and CNS depends on local expression
and secretion of this protein.
In conclusion, S100B released by adipocytes could work
as an adipokine by modulating local microcirculation and
immune response. In fact, due to local activation of the
immune system, some S100 proteins (including S100B)
havebeenconsideredadamage-associatedmolecularpattern
(DAMP) or alarmin [65].
7. Contribution of Adipose Tissue to
the Serum S100B Content
Generally, serum S100B is interpreted as a reﬂex of brain
damage or astroglial activation. This is based on some
properties: (1) brain tissue contains an elevated content of
this protein, particularly in the astrocytes in gray matter;
(2) astrocytes secrete S100B and, in fact, high levels can
be measured in cerebrospinal ﬂuid; (3) S100B is a small
and very soluble protein. However, some points should be
taken into consideration. Oligodendrocytes, choroid plexus
epithelium and ependymal cells contains S100B [12]a n d
potentially contribute to S100B cerebrospinal ﬂuid (CSF)
content.Thesizeandsolubility“perse”doesnotassureafree
traﬃc from astrocytes or CSF to blood. In fact, there is some
evidence that elevations of S100B in cerebrospinal ﬂuid are
not necessarily accompanied by elevation in serum S100B.
The S100B traﬃc likely demands speciﬁc transporters, and
it is possible that some brain diseases allow a higher S100B
eﬄux.
Many extracerebral sources of S100B may contribute to
the serum content of this protein. Here, we have emphasized
adipocytes, but other sources include chondrocytes and cells
of the marrow bone (in case of traumatism) [66, 67]a n d
melanoma cells [68]. In these cases, S100B release appears
to involve cell lysis, rather than actual S100B secretion.
Other S100B-containing cells such as lymphocytes and
cardiomyocytes are unlikely to contribute to serum S100B
content.
Adipose tissue alterations, particularly insulin resistance,
appear to be involved (whether preceding or associated)
in many diseases, including type 2 diabetes, cardiovascular
diseases and dementia [69, 70]. In addition to insulin resis-
tance, adipose tissue alterations are also observed in bipolar
aﬀective disorders and schizophrenic patients [71], which
are accompanied by elevations in serum S100B [39, 72].
Interestingly,insulinresistanceinschizophrenicpatientsmay
be closely linked to serum S100B changes [73]. In support of
this observation, rats fed on a ketogenic diet, which exhibits
signals of insulin resistance [60], also demonstrate elevated
levels of serum S100B (D Ziegler, unpublished observation).
Another important aspect to be considered is the
ontogeny of the S100B protein. Serum S100B levels are
negatively correlated with age [74]. This proﬁle could be
explained by the changes in S100B content in brain tissue
(increase) and cerebrospinal ﬂuid (decrease) observed dur-
ing the postnatal development of rats [75]. Conversely, white
adipose tissues increase with age [7]. This developmental
characteristic apparently contradicts arguments regarding
the contribution of adipocytes to serum S100B content.
However, developmental evaluation of S100B content and
secretion in white adipose tissue has, so far, not been
investigated. Moreover, the contribution of brown adipose
tissue, which contains S100B [76]a n dad e c r e a s ei na na g e -
dependent manner [77], also remains to be characterized.
In conclusion, adipocytes contain high levels of S100B
and in vitro assays indicate a modulated secretion of this
proteinbyhormonesthatregulatelipolysis,suchasglucagon,
adrenaline and insulin. Although the biological signiﬁcance
of extracellular S100B from adipose tissue is still unclear, it is
likely that this tissue might be an important source of serum
S100B in situations related, or not, to brain damage. Current
knowledge does not preclude the use of this protein in serum
as a marker of brain injury or astroglial activation, but
caution is recommended when discussing the signiﬁcance of
changesinitsserumlevels,whereS100Bcouldfunctionasan
adipokine, a neurotrophic cytokine or an alarmin.
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